Expertise in
21
conditions

Dr. Timothy Cloughesy

Neurology
UCLA Health Bowyer Oncology Center
200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 
Clinical Trials:Currently Recruiting for 1 Trial
Offers Telehealth
Expertise in
21
conditions
UCLA Health Bowyer Oncology Center
200 UCLA Medical Plz Ste 120, 
Los Angeles, CA 

Overview

Timothy Cloughesy is a Neurologist in Los Angeles, California. Dr. Cloughesy is highly rated in 21 conditions, according to our data. His top areas of expertise are Glioblastoma, Astrocytoma, Glioma, and Brain Tumor.

His clinical research consists of co-authoring 350 peer reviewed articles and participating in 21 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties

Neurology

Licenses

Psychiatry & Neurology in CA

Hospital Affiliations

Ronald Reagan UCLA Medical Center

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Health Plan of San Mateo
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

UCLA Health Bowyer Oncology Center
200 UCLA Medical Plz Ste 120, Los Angeles, CA 90095
Other Locations
UCLA Health Westwood Neurology
300 UCLA Medical Plz Ste B200, Los Angeles, CA 90095

Additional Areas of Focus

Dr. Cloughesy has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

20 Clinical Trials

Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects With Non-Small Cell Lung Cancer With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
Enrollment Status: Recruiting
Publish Date: June 27, 2025
Intervention Type: Drug
Study Drug: APL-101
Study Phase: Phase 2
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Phase 0/I Study of AMG 232 (KRT 232) Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 (KRT 232) in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters
Enrollment Status: Terminated
Publish Date: November 13, 2025
Intervention Type: Procedure, Drug, Radiation
Study Drug: KRT-232
Study Phase: Phase 1
Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Phase I Surgical Trial to Evaluate Early Immunologic Pharmacodynamic Parameters for the PD-1 Antibody Pembrolizumab With Autologous Tumor Lysate-Pulsed Dendritic Cell Vaccination in Patients With Surgically Accessible Recurrent/Progressive Glioblastoma
Enrollment Status: Active_not_recruiting
Publish Date: August 22, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Poly ICLC
Study Phase: Phase 1
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
A Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of the PI3K/mTOR Inhibitor Paxalisib (GDC-0084) Administered to Patients With Glioblastoma Characterized by Unmethylated O6-methylguanine-methyltransferase Promoter Status Following Surgical Resection and Standard Concomitant Chemoradiation Therapy With Temozolomide
Enrollment Status: Completed
Publish Date: March 24, 2025
Intervention Type: Drug
Study Drug: Paxalisib (GDC-0084)
Study Phase: Phase 2
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Phase I Study of Neoadjuvant GMCI Plus Immune Checkpoint Inhibitor Combined With Standard of Care for Newly Diagnosed High-Grade Gliomas
Enrollment Status: Completed
Publish Date: February 14, 2025
Intervention Type: Radiation, Biological, Other, Drug
Study Drugs: AdV-tk, Valacyclovir, Temozolomide, Nivolumab
Study Phase: Phase 1
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Phase I/II Study of BGB-290 With Temozolomide in Recurrent Gliomas With IDH1/2 Mutations
Enrollment Status: Completed
Publish Date: January 14, 2025
Intervention Type: Drug, Procedure
Study Drugs: BGB-290 PARP Inhibitor, Temozolomide
Study Phase: Phase 1/Phase 2
Oral ONC201 in Adult Recurrent Glioblastoma
Oral ONC201 in Adult Recurrent Glioblastoma
Enrollment Status: Terminated
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drug: ONC201
Study Phase: Phase 2
Creating Metabolic Vulnerabilities in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Osimertinib
Creating Metabolic Vulnerabilities in Patients with EGFR Activated Recurrent Glioblastoma by Inhibiting EGFR with Osimertinib
Enrollment Status: Completed
Publish Date: November 12, 2024
Intervention Type: Drug, Procedure, Other
Study Drug: Osimertinib
Study Phase: Phase 2
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Drug Distribution and Pharmacodynamic Study of Pulsatile Lapatinib in Surgically Accessible EGFR-Amplified Recurrent High-Grade Glioma
Enrollment Status: Completed
Publish Date: November 06, 2024
Intervention Type: Procedure, Other, Drug
Study Drugs: Lapatinib, Lapatinib Ditosylate
Study Phase: Phase 1
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
A Phase II Study of Binimetinib in Combination With Encorafenib in Adults With Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor
Enrollment Status: Terminated
Publish Date: October 31, 2024
Intervention Type: Biological, Drug
Study Drugs: Encorafenib, Binimetinib
Study Phase: Phase 2
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Phase 1/1b Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 596 as Monotherapy and in Combination With AMG 404 in Subjects With Glioblastoma or Malignant Glioma Expressing Mutant Epidermal Growth Factor Receptor Variant III (EGFRvIII)
Enrollment Status: Terminated
Publish Date: October 29, 2024
Intervention Type: Drug
Study Drugs: AMG 596, AMG 404
Study Phase: Phase 1
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination With Anti-PD-1 in Patients With Recurrent GBM
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drugs: Anti-LAG-3 Monoclonal Antibody BMS 986016, Anti-PD-1, Anti-CD137
Study Phase: Phase 1
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients With High Grade Gliomas
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Drug
Study Drug: Regadenoson
Study Phase: Phase 1
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients With Recurrent High Grade Glioma
Enrollment Status: Completed
Publish Date: October 06, 2023
Intervention Type: Other, Drug
Study Drug: Terameprocol
Study Phase: Phase 1
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients With High Grade Gliomas and Severe Treatment-related CD4 Lymphopenia After Concurrent Radiation and Temozolomide
Enrollment Status: Terminated
Publish Date: October 06, 2023
Intervention Type: Biological, Other
Study Drug: NT-I7
Study Phase: Phase 1
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Single-Arm, Open-Label Phase II Efficacy Study of First-in-Class HIF-2 Alpha Inhibitor, PT2385, for Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug, Other
Study Phase: Phase 2
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Enrollment Status: Completed
Publish Date: July 15, 2021
Intervention Type: Biological
Study Drugs: DNX-2401 Adeno-Associated Oncolytic Virus Delta-24 Vaccine, Pembrolizumab
Study Phase: Phase 2
A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
A Phase II Clinical Trial Evaluating Combination Therapy Using DCVax-L (Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen) and Nivolumab (an Anti-PD-1 Antibody) for Subjects With Recurrent Glioblastoma Multiforme
Enrollment Status: Withdrawn
Publish Date: July 24, 2020
Intervention Type: Other, Biological
Study Phase: Phase 2
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma
Enrollment Status: Terminated
Publish Date: February 07, 2020
Intervention Type: Biological, Drug
Study Phase: Phase 2/Phase 3
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma
Enrollment Status: Completed
Publish Date: October 23, 2018
Intervention Type: Drug
Study Phase: Phase 3
View 19 Less Clinical Trials

350 Total Publications

First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
First-in-human study of an EGFRvIII x CD3 T cell bispecific antibody in the treatment of newly diagnosed glioblastoma.
Journal: Neuro-oncology advances
Published: August 22, 2025
Similar Doctors
Expertise in
51
conditions
Dr. Susan Perlman
Neurology
Expertise in
51
conditions
Dr. Susan Perlman
Neurology

Office

300 Medical Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Perlman is a Neurologist in Los Angeles, California. Dr. Perlman is highly rated in 51 conditions, according to our data. Her top areas of expertise are Spinocerebellar Ataxia, Friedreich Ataxia, Drug Induced Dyskinesia, and Olivopontocerebellar Atrophy.

Expertise in
26
conditions
Dr. Phioanh Nghiemphu
Neurology
Expertise in
26
conditions
Dr. Phioanh Nghiemphu
Neurology

Office

200 Med Plz, 
Los Angeles, CA 
 (0.1 miles away)
310-206-6909
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Phioanh Nghiemphu is a Neurologist in Los Angeles, California. Dr. Nghiemphu is highly rated in 26 conditions, according to our data. Her top areas of expertise are Glioma, Astrocytoma, Glioblastoma, and Brain Tumor.

Expertise in
48
conditions
Dr. Perry Shieh
Neurology
Expertise in
48
conditions
Dr. Perry Shieh
Neurology

Office

300 Medical Plz Ste B-200, 
Los Angeles, CA 
 (0.4 miles away)
310-794-1195
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Dr. Perry Shieh, MD is a Neurology Specialist in Los Angeles, CA and has over 22 years of experience in the medical field. He graduated from Johns Hopkins University School Of Medicine in 2000. He is affiliated with medical facilities Ronald Reagan UCLA Medical Center and Casa Colina Hospital. Dr. Shieh is highly rated in 48 conditions, according to our data. His top areas of expertise are Spinal Muscular Atrophy (SMA), Duchenne Muscular Dystrophy, Becker Muscular Dystrophy, and Tubular Aggregate Myopathy.

Frequently Asked Questions about Dr. Timothy Cloughesy

How do I make an appointment with Dr. Timothy Cloughesy?

You can book an appointment with Dr. Timothy Cloughesy by calling their office at 310-206-6909. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Timothy Cloughesy a top-rated expert for Glioblastoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Timothy Cloughesy is classified as an Elite expert for Glioblastoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Timothy Cloughesy specialize in?

While Dr. Timothy Cloughesy is a Neurology, they have specific expertise in Glioblastoma, Astrocytoma, and Glioma. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Neurology.

Does Dr. Timothy Cloughesy participate in research or clinical trials?

Yes. Dr. Timothy Cloughesy has published 350 articles and abstracts on conditions like Glioblastoma. You can view a list of Dr. Timothy Cloughesy's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Timothy Cloughesy accept my insurance?

Dr. Timothy Cloughesy accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 310-206-6909 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Cloughesy's expertise for a condition
ConditionClose
View All 7 Elite Conditions
View All 12 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile